Cannabichromene

CBC potentiated barbiturate- and CNS depressant-induced hypnosis in mice through a pharmacodynamic mechanism independent of CYP inhibition. Its GABAA PAM activity at the β2 subunit V436 site provides a mechanistic basis for additive sedation with benzodiazepines, barbiturates, opioids, alcohol, and general anesthetics. No human data confirms this interaction.

While CBC demonstrated anti-seizure effects via GABAA PAM in animal models, no human dose-response or safety data exist. Patients on anti-epileptic drugs metabolized by CYP2C19 or CYP3A4 (e.g., clobazam, phenytoin, carbamazepine) face unpredictable pharmacokinetic interactions. The absence of human data makes benefit-risk assessment impossible for complex seizure disorders.

Individuals with documented allergic reactions to cannabis-derived compounds (including contact dermatitis, urticaria, or anaphylaxis to cannabis pollen/products) should avoid CBC. No CBC-specific hypersensitivity cases have been reported, but the shared terpenophenolic scaffold across phytocannabinoids makes cross-reactivity plausible.

CBC inhibited FSH-stimulated granulosa cell function in vitro — a direct antigonadal effect shared across psychoactive and non-psychoactive cannabinoids (Adashi 1983). No in vivo reproductive toxicology studies specific to CBC exist. The clinical significance for human fertility, pregnancy, or lactation is unknown.

CBC is a substrate for multiple CYP isoforms (1A2, 2B6, 2C8, 2C19, 2D6, 3A4) but does not significantly inhibit these enzymes. Co-administration with other CYP substrates may produce competitive interactions altering plasma levels of both compounds, as demonstrated with CBC+CBD in rats (mutual Cmax/AUC increases). Strong CYP inhibitors could elevate CBC levels; strong inducers could reduce them.